Clovis Oncology highlighted the US FDA’s “increasing emphasis on overall survival (OS) in oncology trials” as a driving force behind the company’s voluntary withdrawal of one of the indications for the PARP inhibitor Rubraca (rucaparib) effective 10 June 2022.
The withdrawn claim, for treatment of ovarian and related cancers with deleterious BRCA mutations after two or more lines of...







